Topical timolol is a beta-blocker eye drop repurposed as a skin treatment for infantile hemangiomas, the most common vascular tumors of infancy. Applied directly to the surface of the lesion, it can slow growth, reduce redness, and promote shrinkage of small, superficial hemangiomas without the systemic side effects that come with swallowing a pill. A meta-analysis of controlled trials found the treatment response rate was roughly nine times higher in treated infants than in untreated controls, and the drug is generally well tolerated. But timolol is not a one-size-fits-all fix, and what you can expect depends on the hemangioma’s depth, size, location, and how early treatment begins.
Why a Heart Drug Shrinks Birthmarks
Timolol belongs to the beta-blocker family, drugs originally designed to lower blood pressure and heart rate. The connection to hemangiomas was discovered by accident in 2008, when doctors noticed that an infant being treated with oral propranolol for a heart condition also saw dramatic improvement in a hemangioma. Since then, several beta-blockers have been used against these growths, with propranolol taken by mouth and timolol applied to the skin becoming the two workhorses.1PubMed Central. Cardiovascular drugs in the treatment of infantile hemangioma
The exact way beta-blockers cause hemangiomas to regress is still being worked out, but researchers have identified several overlapping mechanisms. These drugs promote constriction of the tiny blood vessels feeding the tumor, block signals that trigger new blood vessel formation, and interfere with a hormonal pathway called the renin-angiotensin system that helps sustain the growth.2British Journal of Dermatology. The use of propranolol in the treatment of infantile haemangiomas: an update on potential mechanisms of action In practical terms, the first thing parents often notice is a color change: the hemangioma turns from bright red to a duller, purplish shade within days, because the blood vessels feeding it are tightening up. Over weeks and months, the lesion flattens and fades further.
How Well Topical Timolol Works
The evidence base for topical timolol has grown steadily over the past decade. A systematic review and meta-analysis pooling data from controlled trials found that infants treated with topical timolol had a response rate about nine times higher than untreated infants, with no significant adverse effects noted across the studies.3PubMed. The Role of Topical Timolol in the Treatment of Infantile Hemangiomas: A Systematic Review and Meta-analysis In one controlled study comparing timolol gel against observation alone, about 62% of treated infants had a good response and another 31% had a moderate response, whereas 90% of untreated infants showed poor response over the same period.4Ophthalmic Plastic & Reconstructive Surgery. A Controlled Study of Topical 0.25% Timolol Maleate Gel for the Treatment of Cutaneous Infantile Capillary Hemangiomas
Early changes can appear quickly. In a case series using 0.5% timolol gel, all treated infants showed growth arrest along with a reduction in redness and thickness within the first two weeks. Most hemangiomas in that series reached near-complete resolution, and regression occurred months earlier than the spontaneous fading typically seen in untreated hemangiomas, which usually does not begin before nine to twelve months of age.5PubMed. Topical timolol for small hemangiomas of infancy A larger retrospective study of 666 infants found that roughly 72% achieved excellent or good outcomes with topical timolol.6PubMed Central. The timing and safety of topical timolol treatment for superficial infantile hemangioma: a retrospective cohort study
Which Hemangiomas Respond Best
Timolol applied to the skin can only reach so deep. That basic physical limitation shapes everything about who benefits most. Superficial hemangiomas, the flat-to-slightly-raised bright red “strawberry” type, respond well because the drug can penetrate directly into the abnormal vessels. Mixed or deep hemangiomas, which extend beneath the skin surface, respond less reliably to topical treatment because the medication simply cannot reach the deeper portions of the growth.7PubMed Central. Infantile haemangioma: topical timolol
Size and timing also matter. In the large 666-patient cohort study, infants who started treatment at three months of age or younger had significantly better outcomes than those who began later, and smaller hemangiomas fared better than larger ones.6PubMed Central. The timing and safety of topical timolol treatment for superficial infantile hemangioma: a retrospective cohort study That said, there is an interesting wrinkle about very early treatment. A randomized clinical trial specifically testing timolol in the first two months of life, during the earliest proliferative phase, found that while the drug was well tolerated, it provided limited benefit in actually preventing further growth at that very early stage.8JAMA Dermatology. Efficacy and Safety of Topical Timolol for the Treatment of Infantile Hemangioma in the Early Proliferative Stage: A Randomized Clinical Trial The practical takeaway is that starting before three months is generally better than waiting, but applying timolol to a brand-new lesion in the first few weeks of life may not head off growth the way parents hope.
Timolol Versus Oral Propranolol
For parents whose child has been diagnosed with a hemangioma, one of the first questions is whether the topical version is enough or whether the oral medication is necessary. The answer hinges on what kind of hemangioma it is. A meta-analysis and systematic review published in 2024 found that oral propranolol produced a higher overall response rate than topical timolol, but it also came with roughly double the risk of side effects.9Frontiers in Pharmacology. Efficacy and safety of oral propranolol and topical timolol in the treatment of infantile hemangioma: a meta-analysis and systematic review When the analysis looked specifically at superficial hemangiomas, that efficacy gap disappeared: timolol matched propranolol’s effectiveness while still carrying fewer adverse events.9Frontiers in Pharmacology. Efficacy and safety of oral propranolol and topical timolol in the treatment of infantile hemangioma: a meta-analysis and systematic review
A separate head-to-head comparison of 362 propranolol patients and 362 timolol patients with superficial hemangiomas reached a similar conclusion, finding no significant difference in outcomes between the two treatments.10Frontiers in Oncology. Topical Timolol Vs. Oral Propranolol for the Treatment of Superficial Infantile Hemangiomas Another meta-analysis of randomized controlled trials confirmed that topical beta-blockers were as effective as oral propranolol for superficial hemangiomas and outperformed placebo, corticosteroids, and pulsed dye laser alone, all while being associated with far fewer side effects.11Dermatology. The Efficacy and Safety of Topical β-Blockers in Treating Infantile Hemangiomas: A Meta-Analysis Including 11 Randomized Controlled Trials
So for a small, flat, superficial hemangioma, topical timolol is a reasonable first-line choice that avoids the sleep disturbance, low blood sugar, and gastrointestinal upset that can accompany oral propranolol. For deeper, larger, or more complicated hemangiomas, especially those threatening vision, breathing, or feeding, oral propranolol remains the stronger tool.
Safety and Systemic Absorption
One of the main selling points of topical timolol is that it stays mostly local. But “mostly” deserves a closer look. When researchers tested the urine of 24 infants being treated with topical timolol, 83% had detectable timolol in their urine. Blood levels were checked in three infants and were positive in all of them, though the concentrations were very low.12PubMed. Topical Timolol for Infantile Hemangiomas: Evidence for Efficacy and Degree of Systemic Absorption A pharmacokinetic modeling study confirmed that systemic exposure from the topical gel formulation is limited, supporting a favorable safety profile for infants with superficial hemangiomas.13PubMed Central. Population Pharmacokinetics of Topical Timolol Maleate Gel in Healthy Volunteers and Infants With Superficial Infantile Hemangioma
Low absorption does not mean zero risk, though. In a study monitoring infants with Holter heart monitors during timolol treatment, four babies developed episodes of bradycardia (abnormally slow heart rate). Two of those infants were full-term and weighed over 3,000 grams; their episodes were rare, brief, and asymptomatic, unrelated to the timing of timolol application. The other two babies, however, had symptomatic bradycardia, and both weighed under 2,500 grams when treatment started.14PubMed. Adverse Events in Young and Preterm Infants Receiving Topical Timolol for Infantile Hemangioma That finding suggests that very small or premature infants are at higher risk from even small amounts of systemic absorption, and closer monitoring is warranted in that group.
Ulcerated hemangiomas pose a particular concern for absorption. When the skin surface is broken, more drug can pass into the bloodstream. Researchers have advised extra caution with ulcerated or very large hemangiomas, and some recommend monitoring temperature, blood pressure, and heart rate for a few hours after application in preterm or young infants.15Journal of Clinical and Aesthetic Dermatology. Complications of Topical Timolol in the Management of Infantile Hemangiomas: A Systematic Review
How Timolol Is Applied
Topical timolol for hemangiomas is typically applied as either a solution or a gel-forming solution, with concentrations of 0.25% or 0.5%. The most common routine is to place a drop on the hemangioma and gently spread it over the surface, usually two to three times a day. Some providers prefer gel formulations because they stay in place on the skin longer, though practice varies. No single protocol has been universally standardized, and the approach your child’s doctor recommends will depend on the hemangioma’s size, location, and characteristics.
One practical concern that does not get enough attention is how much medication actually comes out of the bottle. A study measuring the delivery of timolol from dropper bottles found significant differences between solution and gel-forming solution. The gel-forming version delivered amounts closer to what the manufacturer intended, but it also showed greater variability between drops and between users.16PubMed. Variability of Delivery of Timolol for the Treatment of Infantile Hemangiomas For parents, this means the amount of drug reaching the hemangioma may differ depending on which formulation you use and how you apply it. Asking your child’s provider for specific application instructions, and sticking with the same formulation throughout treatment, helps keep things consistent.
Treatment duration varies but is generally measured in months. Many clinicians continue timolol through the proliferative phase of the hemangioma (roughly the first year of life) and taper or stop once the lesion is clearly involuting. Because infantile hemangiomas naturally begin to shrink on their own, usually starting between nine and twelve months, there can be some ambiguity about how much of the improvement is from the drug and how much would have happened anyway. That is part of why controlled studies matter so much in evaluating this treatment.
Periocular and Other Sensitive Locations
Hemangiomas near the eye are especially worrisome because they can press on the eyeball and cause astigmatism, amblyopia, or other vision problems. Oral propranolol is commonly used here, but timolol gel offers an alternative when systemic treatment is contraindicated or when the hemangioma is thin and superficial. A case report of timolol 0.1% gel applied to an eyelid hemangioma described it as safe and effective, and the authors suggested it could be a valuable option for periocular lesions in infants who cannot take oral medication.17Actas Dermo-Sifiliográficas. Infantile Hemangioma of the Eyelid Treated with Timolol Gel Still, periocular hemangiomas that are large or deep typically need oral propranolol, because the stakes for vision are high and timolol cannot reliably penetrate deep tissue.
Similar logic applies to hemangiomas near the nose, lips, or other areas where the growth could affect function. If the hemangioma is superficial and small, topical timolol may be sufficient. If it is bulky or threatens to obstruct an airway or distort a structure, the systemic medication remains the standard approach. The decision is not always clear-cut, and sometimes treatment begins with topical timolol and escalates to oral propranolol if the hemangioma continues growing.
Combining Timolol with Pulsed Dye Laser
Some clinicians combine topical timolol with pulsed dye laser treatment, particularly for hemangiomas that have residual redness or telangiectasia after initial improvement. In a Korean study of 102 infants, those treated with timolol alone showed about 47% improvement from baseline, while those receiving timolol plus pulsed dye laser achieved about 67% improvement. Neither group experienced side effects.18PubMed. Topical timolol maleate 0.5% for infantile hemangioma; it’s effectiveness and/or adjunctive pulsed dye laser – single center experience of 102 cases in Korea A broader meta-analysis of randomized trials confirmed that topical beta-blockers combined with another intervention produced better clinical responses in mixed (deeper) hemangiomas than either treatment alone.11Dermatology. The Efficacy and Safety of Topical β-Blockers in Treating Infantile Hemangiomas: A Meta-Analysis Including 11 Randomized Controlled Trials
Timing of the laser component matters too. A study that paired pulsed dye laser with 0.5% timolol solution found that starting the combination earlier in the growth phase resulted in more temporary side effects from the laser (like bruising and swelling) but far fewer permanent complications compared to starting later.19PubMed Central. Timing and Efficacy of 595-nm Pulsed-Dye Laser Combined with 0.5% Timolol Maleate Solution in the Treatment of Superficial Infantile Hemangiomas In other words, early combination treatment may cause more short-term redness and swelling around the laser site, but it is less likely to leave lasting marks.
When Timolol May Not Be Enough
Parents sometimes assume that because hemangiomas are classified as “benign,” any treatment including the gentlest option will be fine. There are situations where timolol alone is unlikely to do the job. Large hemangiomas covering a wide surface area absorb more drug systemically and still may not respond fully, because the topical agent cannot reach all the abnormal tissue. Segmental hemangiomas, which spread across a body region in a geographic pattern, typically require oral treatment or other interventions. So do hemangiomas associated with PHACE syndrome (a condition involving hemangiomas along with brain, heart, and arterial abnormalities), which demand a broader medical workup and systemic therapy.
Hemangiomas that have already ulcerated present a different challenge. While timolol has been applied to ulcerated lesions, the broken skin increases the risk of systemic absorption, and the ulcer itself often needs wound care that complicates topical drug application.15Journal of Clinical and Aesthetic Dermatology. Complications of Topical Timolol in the Management of Infantile Hemangiomas: A Systematic Review In these cases, propranolol by mouth often becomes necessary, with or without topical timolol as an adjunct.
The Emotional Side of Treatment
What rarely gets discussed in clinical papers is how stressful the treatment period is for families. Infantile hemangiomas grow rapidly in the first few months of life, often alarming parents even when doctors explain they are benign. Applying drops to a squirming infant’s face or scalp multiple times a day is not trivial, and the slow pace of improvement can feel agonizing when you are looking at your child’s face every day. Research following families after hemangioma treatment with beta-blockers has found that parents of treated children reported more stress in the parent-child relationship, increased low mood, and more physical health problems themselves compared to parents of untreated children. That finding is a reminder that the decision to treat is not just about the lesion’s medical trajectory: it should account for the burden on the family as well.
Many parents also struggle with the watch-and-wait recommendation when their child’s hemangioma is not severe enough to warrant treatment. Since most hemangiomas do eventually shrink on their own, sometimes the hardest part is accepting that the best course of action may be no treatment at all, particularly for small, flat lesions in low-risk locations. Timolol has filled a useful middle ground here: it is gentler than oral medication, relatively easy to apply, and gives parents a sense of actively doing something about a lesion that might otherwise just be monitored. Whether that psychological benefit should factor into treatment decisions is a question clinicians weigh differently, but it is part of the real-world experience of managing these growths.